U.S. Markets open in 13 hrs, 48 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,430.21 | 12.78 | 0.11% |
| NASDAQ | 2,380.38 | -8.70 | -0.36% |
| S&P 500 | 1,277.72 | 3.18 | 0.25% |
| Day Low 11:33 AM EDT | 41.06 | |
|---|---|---|
| Day High 09:30 AM EDT | 42.07 |
|
| Range | 1.01 | |
| Volume | 861,846 | |
| 30-Day Avg. Vol. | 1.88 M |
|
| Difference | -54.18% | |
| Market Cap. | 2.33 B | |
| Change | -29.19 M | |
| Shares Out. | 55.57 M | |
| Percent Traded | 1.54% | |
| Revenue | 0 | |
| Earnings | -34.16 M | |
| EPS (TTM) | 0.17 |
| 52-Wk Low 3/10/08 | 24.60 | |
|---|---|---|
| 52-Wk High 11/14/07 | 61.18 |
|
| Range | 36.58 | |
| Prev. Close 8/20/08 | 42.09 | |
| Today's Open | 41.88 | |
| Change | -0.50% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.4096 | |
| P/E Ratio (TTM) | 244.53 | |
| P/E Ratio (Fwd.) | 59.00 |
Onyx Pharmaceuticals' cancer drug could turn out to be a real gem. Working with health care behemoth Bayer, the biotechnology company developed Nexavar, an FDA-approved treatment for advanced kidney cancer ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.06 3/31/08 | 0.27 3/31/08 |
0.33
Beat
|
| Last Quarter | 0.065 6/30/08 | 0.08 6/30/08 |
0.015
Beat
|
| Quarterly - 06/30/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 30.20 M | 0.00 |
| Gross Profit | -8.58 M | -1.03 M |
| Operating Income | 1.75 M | -85.96 M |
| Net Income | 4.47 M | -34.17 M |
Real-Time Quote
